‘Business Report’: Regenerating TransGenRx


    Last summer, TransGenRx was in bankruptcy court, owing almost $7.9 million. Today, its core technology survives as the basis of a new company called ProteoVec. As Business Report details in its curren…

    Already a subscriber? .

    We are glad you enjoy reading Business Report.

    Continue reading this story and get ACCESS to all our content from any device with a subscription now.

    • Get access to more than a decade of story archives.
    • Get access to our searchable data center of TOP LISTS.
    • Get exclusive content only available to INSIDERS.